Home
>
US Stocks
>
WEREWOLF THERAPEUTICS INC

WEREWOLF THERAPEUTICS INC (HOWL)

$3.59

-0.06

(-1.64%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on WEREWOLF THERAPEUTICS INC

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 4.14M → 7.28M (in $), with an average increase of 24.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -11.93M → -11.98M (in $), with an average decrease of 0.4% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 39.6% return, outperforming this stock by 55.5%

Performance

  • $3.51
    $3.89
    $3.59
    downward going graph

    2.23%

    Downside

    Day's Volatility :9.76%

    Upside

    7.71%

    downward going graph
  • $1.39
    $7.51
    $3.59
    downward going graph

    61.28%

    Downside

    52 Weeks Volatility :81.49%

    Upside

    52.2%

    downward going graph

Returns

PeriodWEREWOLF THERAPEUTICS INCSector (Health Care)Index (Russel 2000)
3 Months
44.18%
0.9%
-8.3%
6 Months
105.14%
-6.8%
-6.5%
1 Year
-12.44%
0.4%
-6.1%
3 Years
-77.7%
28.3%
21.8%

Highlights

Market Capitalization
127.8M
Book Value
$3.43
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.88
Wall Street Target Price
11.86
Profit Margin
-241.79%
Operating Margin TTM
-253.6%
Return On Assets TTM
-18.39%
Return On Equity TTM
-38.75%
Revenue TTM
20.9M
Revenue Per Share TTM
0.68
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-37.4M
EBITDA
-51.5M
Diluted Eps TTM
-1.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.69
EPS Estimate Next Year
-1.76
EPS Estimate Current Quarter
-0.5
EPS Estimate Next Quarter
-0.34

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for WEREWOLF THERAPEUTICS INC(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 230.36%

Current $3.59
Target $11.86

Technicals Summary

Sell

Neutral

Buy

WEREWOLF THERAPEUTICS INC is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
WEREWOLF THERAPEUTICS INC
WEREWOLF THERAPEUTICS INC
38.08%
105.14%
-12.44%
-77.7%
-77.7%
Moderna, Inc.
Moderna, Inc.
-2.84%
-25.82%
-6.78%
115.4%
601.67%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.85%
-2.05%
21.5%
23.63%
137.1%
Seagen, Inc.
Seagen, Inc.
-1.57%
61.18%
37.09%
29.88%
217.64%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.7%
5.09%
24.54%
22.34%
123.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
WEREWOLF THERAPEUTICS INC
WEREWOLF THERAPEUTICS INC
0.66
NA
NA
-1.69
-0.39
-0.18
0.0
3.43
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
WEREWOLF THERAPEUTICS INC
WEREWOLF THERAPEUTICS INC
Buy
$127.8M
-77.7%
0.66
-241.79%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
601.67%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
137.1%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
217.64%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
123.04%
26.18
35.4%

Institutional Holdings

  • RA Capital Management, LLC

    17.30%

  • Mpm Asset Management, LLC

    12.06%

  • MPM Oncology Impact Management LP

    6.72%

  • Rubric Capital Management LP

    5.45%

  • Bank of America Corp

    4.32%

  • Partner Fund Management LP

    3.64%

Company Information

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Organization
WEREWOLF THERAPEUTICS INC
Employees
46
CEO
Dr. Daniel J. Hicklin Ph.D.
Industry
Healthcare

Discover More

FAQs